°ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2025-2032³â)
Irritable Bowel Syndrome Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032
»óǰÄÚµå
:
1776824
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2025³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 192 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â ÃÖ±Ù ¼¼°è °ú¹Î¼º ´ëÀå ÁõÈıº ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» ¹ßÇ¥Çß½À´Ï´Ù.
ÀÌ º¸°í¼´Â ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ-µ¿Çâ-±âȸ-°úÁ¦ µî ÁÖ¿ä ½ÃÀå ¿ªÇп¡ ´ëÇÑ Ã¶ÀúÇÑ Æò°¡¿Í ÇÔ²² ½ÃÀå ±¸Á¶¿¡ ´ëÇÑ »ó¼¼ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
°ú¹Î¼º´ëÀåÁõÈıº ½ÃÀå ±Ô¸ð(2025³â) : 42¾ï ´Þ·¯
½ÃÀå ±Ô¸ð ¿¹Ãø(±Ý¾× ±â¹Ý, 2032³â) : 74¾ï ´Þ·¯
¼¼°è ½ÃÀåÀÇ ¼ºÀå·ü(CAGR, 2025-2032³â) : 8.5%
°ú¹Î¼º ´ëÀå ÁõÈıº ½ÃÀå - ºÐ¼® ¹üÀ§
°ú¹Î¼º ´ëÀå ÁõÈıº Ä¡·áÁ¦ ½ÃÀå¿¡´Â º¯ºñ µ¿¹Ý IBS(IBS-C), ¼³»ç µ¿¹Ý IBS(IBS-D), È¥ÇÕÇü(IBS-M) µî IBSÀÇ ÇÏÀ§ À¯ÇüÀ» °ü¸®Çϱâ À§ÇØ °í¾ÈµÈ ´Ù¾çÇÑ ¾à¸®ÇÐÀû ¹× ºñ¾à¸®ÇÐÀû Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ.
Ä¡·áÁ¦¿¡´Â Áø°æÁ¦, ¿ÏÇÏÁ¦, Áö»çÁ¦, Ç׿ì¿ïÁ¦, ÇÁ·Î¹ÙÀÌ¿Àƽ½º, »õ·Î¿î Ç¥ÀûÄ¡·áÁ¦ µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ ½ÃÀåÀº º´¿ø, ¼Òȱâ Ŭ¸®´Ð, ÀçÅÃÄ¡·á¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
¼ºÀåÀÇ ¿øµ¿·ÂÀº Àü ¼¼°è IBS À¯º´·ü Áõ°¡, À§Àå °Ç°¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, Àå³»¼¼±ÕÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â Ä¡·á¹ýÀÇ ±â¼ú Çõ½ÅÀÇ ÁøÀüÀÔ´Ï´Ù.
½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ:
¼¼°è °ú¹Î¼º ´ëÀå ÁõÈıº Ä¡·áÁ¦ ½ÃÀåÀº ÁÂ½Ä »ýȰ½À°ü, ½ºÆ®·¹½º, ½Ä½À°ü ºÒ±ÕÇüÀ¸·Î ÀÎÇÑ ¼Òȱâ Áúȯ ¹ßº´·ü Áõ°¡ µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
¼ÒºñÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁö°í Áø´ÜÀ²ÀÌ ³ô¾ÆÁü¿¡ µû¶ó È¿°úÀûÀÎ Áõ»ó °ü¸®¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
¶ÇÇÑ Àå ÁöÇ⼺ Ç×»ýÁ¦, ¼¼·ÎÅä´Ñ ¼ö¿ëü ¸ðµâ·¯ µî Ä¡·á Á¦Á¦ÀÇ ¹ßÀüÀ¸·Î ȯÀÚÀÇ ¿¹ÈÄ¿Í Ä¡·á ¼øÀÀµµ°¡ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
±ÔÁ¦ ´ç±¹ÀÇ ½Å¾à ½ÂÀΰú ½ÃÆÇ ÁßÀÎ Ä¡·áÁ¦¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë´Â ½ÃÀå È®´ë¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ:
À¯¸Á ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸Çϰí IBS Ä¡·áÁ¦ ½ÃÀåÀº ¸î °¡Áö ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù.
IBSÀÇ º´Å»ý¸®¿¡ ´ëÇÑ ÀÌÇØ°¡ Á¦ÇÑÀûÀÌ¾î¼ °áÁ¤ÀûÀÎ Ä¡·á¹ý °³¹ßÀ» °¡·Î¸·°í ÀÖÀ¸¸ç, Áõ»óÀÇ ºÒ±ÕÀϼºÀÌ Ä¡·á Á¢±Ù¹ýÀ» º¹ÀâÇÏ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ Æ¯Á¤ ¾à¹°ÀÇ Àå±â »ç¿ë¿¡ µû¸¥ ºÎÀÛ¿ë°ú ±Ùº»ÀûÀÎ ÇØ°áÃ¥ÀÇ ºÎÁ·À¸·Î ÀÎÇØ ´õ ±¤¹üÀ§ÇÑ ½ÃÀåÀ¸·ÎÀÇ Ä§Åõ¸¦ Á¦ÇÑÇϰí ÀÖ½À´Ï´Ù.
½ÅÈï ±¹°¡¿¡¼´Â Àü¹® ÀÇ·á¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ Á¦ÇѵǾî ÀÖ°í, IBS Áõ»ó¿¡ ´ëÇÑ ÀνÄÀÌ ³·±â ¶§¹®¿¡ Áø´Ü°ú Ä¡·áÀÇ º¸±Þ¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ:
°ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á¿Í Àå³úÃà¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Å« ¼ºÀå ±âȸ¸¦ °¡Á®´Ù ÁÙ °ÍÀÔ´Ï´Ù.
¸¶ÀÌÅ©·Î¹ÙÀÌ¿È Á¶Àý, Àú FODMAP ½Ä´Ü µî ½ÄÀÌ ÁßÀç¿¡ ´ëÇÑ ºÐ¼®À¸·Î »õ·Î¿î Ä¡·áÀÇ ±æÀÌ ¿¸®°í ÀÖ½À´Ï´Ù.
¸ð¹ÙÀÏ °Ç° ¾Û, ¿ø°Ý Áø·á µî µðÁöÅÐ °Ç° ÅøÀº ȯÀÚ Âü¿©¿Í Áõ»ó ÃßÀûÀ» °ÈÇϰí ÀÖ½À´Ï´Ù.
Á¦¾à»ç ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷Àº IBS ¾ÆÇüÀ» Ÿ°ÙÀ¸·Î ÇÑ ½Å¾à ÆÄÀÌÇÁ¶óÀÎ ¹× ÀÓ»ó½ÃÇè¿¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â ÇâÈÄ ½ÃÀå ÆÇµµ¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´äº¯À» ¾òÀ» ¼ö ÀÖ´Â ÁÖ¿ä Áú¹®
°ú¹Î¼º ´ëÀå ÁõÈıº Ä¡·áÁ¦ ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
°¢ Áö¿ªÀÇ Ä¡·á µµÀÔ¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â Ä¡·á À¯Çü°ú ȯÀÚ ÇÏÀ§ ±×·ìÀº ¹«¾ùÀΰ¡?
±â¼ú-¾àÇÐ ¹ßÀüÀº IBS Ä¡·áÁ¦ÀÇ Àü¸ÁÀ» ¾î¶»°Ô ¹Ù²Ù°í Àִ°¡?
IBS Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾î¶² ȸ»çµéÀÌ ÀÖÀ¸¸ç, ¾î¶² Àü·«Àû ±¸»óÀ» ÃëÇϰí Àִ°¡?
¼¼°è IBS Ä¡·áÁ¦ ½ÃÀåÀÇ »õ·Î¿î µ¿Çâ°ú ÇâÈÄ Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°è GDP ¼ºÀå Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ : °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ºÐ¼®
±ÔÁ¦ »óȲ
ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
Á¦Ç° äÅà ºÐ¼®
¹ë·ùüÀÎ ºÐ¼®
Á¦Á¶¾÷üÀÇ ÁÖ¿ä ÇÁ·Î¸ð¼Ç Àü·«
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð ¿¹Ãø(¼ö·® ±â¹Ý)
½ÃÀå ±Ô¸ð¿Í Àü³â´ëºñ ¼ºÀå·ü(±Ý¾× ±â¹Ý)
Àý´ëÀû ¸ÅÃâ ±âȸ
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø(±Ý¾× ±â¹Ý)
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼®(±Ý¾× ±â¹Ý, 2019-2024³â)
ÇöÀç ½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø(±Ý¾× ±â¹Ý, 2025-2032³â)
¼¼°èÀÇ °ú¹Î¼º´ëÀåÁõÈıº ½ÃÀå Àü¸Á : Á¦Ç°º°
¼·Ð/ÁÖ¿ä ºÐ¼® °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Á¦Ç°º°(±Ý¾× ±â¹Ý, 2019-2024³â)
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Á¦Ç°º°(±Ý¾× ±â¹Ý, 2025-2032³â)
½ÄÀ̼¶À¯ º¸ÃæÁ¦
Áö»çÁ¦
Ç×Äݸ°Á¦¡¤Ç×°æ·Ã¾à
Ç׿ì¿ïÁ¦
Ç×»ýÁ¦
Alosetron
Lubiprostone
Linaclotide
NHE3
½ÃÀå ¸Å·Â ºÐ¼® : Á¦Ç°º°
¼¼°èÀÇ °ú¹Î¼º´ëÀåÁõÈıº ½ÃÀå Àü¸Á : ÀûÀÀÁõº°
¼·Ð/ÁÖ¿ä ºÐ¼® °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : ÀûÀÀÁõº°(±Ý¾× ±â¹Ý, 2019-2024³â)
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : ÀûÀÀÁõº°(±Ý¾× ±â¹Ý, 2025-2032³â)
º¯ºñ¸¦ ¼ö¹ÝÇÏ´Â °ú¹Î¼º´ëÀåÁõÈıº
¼³»ç¸¦ ¼ö¹ÝÇÏ´Â °ú¹Î¼º´ëÀåÁõÈıº
È¥ÇÕÇü °ú¹Î¼º´ëÀåÁõÈıº
½ÃÀå ¸Å·Â ºÐ¼® : ÀûÀÀÁõº°
¼¼°èÀÇ °ú¹Î¼º´ëÀåÁõÈıº ½ÃÀå Àü¸Á : À¯Åë ä³Îº°
¼·Ð/ÁÖ¿ä ºÐ¼® °á°ú
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : À¯Åë ä³Îº°(±Ý¾× ±â¹Ý, 2019-2024³â)
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : À¯Åë ä³Îº°(±Ý¾× ±â¹Ý, 2025-2032³â)
º´¿ø ¾à±¹
¼Ò¸Å ¾à±¹
µå·¯±×½ºÅä¾î
¿Â¶óÀÎ ¾à±¹¡¤Á¡Æ÷
ÇÏÀÌÆÛ¸¶ÄÏ¡¤½´ÆÛ¸¶ÄÏ
½ÃÀå ¸Å·Â ºÐ¼® : À¯Åë ä³Îº°
Á¦5Àå ¼¼°èÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á : Áö¿ªº°
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð ºÐ¼® : Áö¿ªº°(±Ý¾× ±â¹Ý, 2019-2024³â)
½ÃÀå ±Ô¸ð ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°(±Ý¾× ±â¹Ý, 2025-2032³â)
ºÏ¹Ì
À¯·´
¾Æ½Ã¾ÆÅÂÆò¾ç
³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀå ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦7Àå À¯·´ÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦9Àå ³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾ÆÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå Àü¸Á :
Á¦12Àå °æÀï ±¸µµ
½ÃÀå Á¡À¯À² ºÐ¼®(2025³â)
½ÃÀå ±¸Á¶
°æÀï °µµ ¸Ê : ½ÃÀ庰
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ : °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
Pfizer, Inc.
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Abbott Laboratories
Novartis AG
AstraZeneca PLC
Ironwood Pharmaceuticals Inc. and Allergan Plc
Bausch Health Companies Inc.
GlaxoSmithKline, Plc.
Lexicon Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Á¦13Àå ºÎ·Ï
ºÐ¼® ¹æ¹ý
ºÐ¼® ÀüÁ¦
µÎÀÚ¾î¿Í ¾à¾î
KSA
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently released a comprehensive report on the worldwide market for irritable bowel syndrome (IBS) treatment. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.
Key Insights:
Irritable Bowel Syndrome Treatment Market Size (2025E): USD 4.2 Billion
Projected Market Value (2032F): USD 7.4 Billion
Global Market Growth Rate (CAGR 2025 to 2032): 8.5%
Irritable Bowel Syndrome Treatment Market - Report Scope:
The irritable bowel syndrome treatment market encompasses a variety of pharmacological and non-pharmacological therapies designed to manage IBS subtypes, including IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed-type (IBS-M). Treatments include antispasmodics, laxatives, antidiarrheals, antidepressants, probiotics, and newer targeted therapies. The market caters to hospitals, gastroenterology clinics, and homecare settings. Growth is driven by increasing global prevalence of IBS, rising awareness regarding gastrointestinal health, and ongoing innovations in gut microbiome-targeted therapies.
Market Growth Drivers:
The global irritable bowel syndrome treatment market is propelled by several key factors, including rising incidences of digestive disorders driven by sedentary lifestyles, stress, and dietary imbalances. Growing consumer awareness and increasing diagnosis rates have elevated demand for effective symptom management. Additionally, advancements in treatment formulations, including gut-directed antibiotics and serotonin receptor modulators, are improving patient outcomes and treatment adherence. Regulatory approvals of new drugs and expanding access to over-the-counter treatments further fuel market expansion.
Market Restraints:
Despite promising growth prospects, the IBS treatment market faces several challenges. Limited understanding of IBS pathophysiology hampers definitive treatment development, and the heterogeneity of symptoms complicates therapeutic approaches. Furthermore, side effects associated with long-term use of certain medications and lack of curative solutions restrict broader market penetration. In emerging economies, limited access to specialized care and low awareness of IBS symptoms pose barriers to diagnosis and treatment uptake.
Market Opportunities:
The irritable bowel syndrome treatment market presents substantial growth opportunities driven by the rising interest in personalized medicine and the gut-brain axis. Research into microbiome modulation and dietary interventions, such as low FODMAP diets, is opening new therapeutic avenues. Digital health tools, including mobile health apps and remote consultations, are enhancing patient engagement and symptom tracking. Pharmaceutical and biotechnology companies are increasingly investing in novel drug pipelines and clinical trials targeting IBS subtypes, which is expected to shape the future market landscape.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the irritable bowel syndrome treatment market globally?
Which treatment types and patient subgroups are influencing therapy adoption across different regions?
How are technological and pharmacological advancements reshaping the IBS treatment landscape?
Who are the key players in the IBS treatment market, and what strategic initiatives are they undertaking?
What are the emerging trends and future prospects in the global IBS treatment market?
Competitive Intelligence and Business Strategy:
These companies are investing in the development of novel agents such as guanylate cyclase-C agonists, chloride channel activators, and serotonin receptor antagonists. Strategic collaborations with academic institutions and licensing partnerships are fostering pipeline development. Furthermore, efforts to improve patient education and promote early diagnosis are critical to strengthening market penetration and patient outcomes.
Key Companies Profiled:
Takeda Pharmaceutical Company Limited
Pfizer, Inc.
Abbott Laboratories
Novartis AG
AstraZeneca PLC
Ironwood Pharmaceuticals Inc. and Allergan Plc
Bausch Health Companies Inc.
GlaxoSmithKline, Plc.
Lexicon Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Irritable Bowel Syndrome Treatment Market Research Segmentation:
By Product
Fiber Supplements
Anti-diarrheal
Anticholinergic and Antispasmodic
Antidepressant
Antibiotics
Alosetron
Lubiprostone
Linaclotide
NHE3
By Indication
Irritable Bowel Syndrome with Constipation
Irritable Bowel Syndrome with Diarrhea
Irritable Bowel Syndrome with alternating Constipation and Diarrhea
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies and Stores
Hypermarkets and Supermarkets
By Region
North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Irritable Bowel Syndrome Treatment Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Pipeline Analysis
3.3. Product Adoption Analysis
3.4. Value Chain Analysis
3.5. Key Promotional Strategies by Manufacturers
3.6. PESTLE Analysis
3.7. Porter's Five Force Analysis
4. Irritable Bowel Syndrome Treatment Market Outlook:
4.1. Key Highlights
4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Bn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
4.2.2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
4.3. Global Irritable Bowel Syndrome Treatment Market Outlook: Product
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Bn) Analysis, By Product, 2019-2024
4.3.3. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
4.3.3.1. Fiber Supplements
4.3.3.2. Anti-diarrheal
4.3.3.3. Anticholinergic and Antispasmodic
4.3.3.4. Antidepressant
4.3.3.5. Antibiotics
4.3.3.6. Alosetron
4.3.3.7. Lubiprostone
4.3.3.8. Linaclotide
4.3.3.9. NHE3
4.3.4. Market Attractiveness Analysis: Product
4.4. Global Irritable Bowel Syndrome Treatment Market Outlook: Indication
4.4.1. Introduction / Key Findings
4.4.2. Historical Market Size (US$ Bn) Analysis, By Indication, 2019-2024
4.4.3. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
4.4.3.1. Irritable Bowel Syndrome with Constipation
4.4.3.2. Irritable Bowel Syndrome with Diarrhea
4.4.3.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
4.4.4. Market Attractiveness Analysis: Indication
4.5. Global Irritable Bowel Syndrome Treatment Market Outlook: Distribution Channel
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
4.5.3. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
4.5.3.1. Hospital Pharmacies
4.5.3.2. Retail Pharmacies
4.5.3.3. Drug Stores
4.5.3.4. Online Pharmacies and Stores
4.5.3.5. Hypermarkets and Supermarkets
4.5.4. Market Attractiveness Analysis: Distribution Channel
5. Global Irritable Bowel Syndrome Treatment Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
5.3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Irritable Bowel Syndrome Treatment Market Outlook:
6.1. Key Highlights
6.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
6.2.1. By Product
6.2.2. By Indication
6.2.3. By Distribution Channel
6.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
6.3.1. U.S.
6.3.2. Canada
6.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
6.4.1. Fiber Supplements
6.4.2. Anti-diarrheal
6.4.3. Anticholinergic and Antispasmodic
6.4.4. Antidepressant
6.4.5. Antibiotics
6.4.6. Alosetron
6.4.7. Lubiprostone
6.4.8. Linaclotide
6.4.9. NHE3
6.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
6.5.1. Irritable Bowel Syndrome with Constipation
6.5.2. Irritable Bowel Syndrome with Diarrhea
6.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
6.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
6.6.1. Hospital Pharmacies
6.6.2. Retail Pharmacies
6.6.3. Drug Stores
6.6.4. Online Pharmacies and Stores
6.6.5. Hypermarkets and Supermarkets
6.7. Market Attractiveness Analysis
7. Europe Irritable Bowel Syndrome Treatment Market Outlook:
7.1. Key Highlights
7.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Product
7.2.3. By Indication
7.2.4. By Distribution Channel
7.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkey
7.3.8. Rest of Europe
7.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
7.4.1. Fiber Supplements
7.4.2. Anti-diarrheal
7.4.3. Anticholinergic and Antispasmodic
7.4.4. Antidepressant
7.4.5. Antibiotics
7.4.6. Alosetron
7.4.7. Lubiprostone
7.4.8. Linaclotide
7.4.9. NHE3
7.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
7.5.1. Irritable Bowel Syndrome with Constipation
7.5.2. Irritable Bowel Syndrome with Diarrhea
7.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
7.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
7.6.1. Hospital Pharmacies
7.6.2. Retail Pharmacies
7.6.3. Drug Stores
7.6.4. Online Pharmacies and Stores
7.6.5. Hypermarkets and Supermarkets
7.7. Market Attractiveness Analysis
8. East Asia Irritable Bowel Syndrome Treatment Market Outlook:
8.1. Key Highlights
8.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Product
8.2.3. By Indication
8.2.4. By Distribution Channel
8.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
8.4.1. Fiber Supplements
8.4.2. Anti-diarrheal
8.4.3. Anticholinergic and Antispasmodic
8.4.4. Antidepressant
8.4.5. Antibiotics
8.4.6. Alosetron
8.4.7. Lubiprostone
8.4.8. Linaclotide
8.4.9. NHE3
8.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
8.5.1. Irritable Bowel Syndrome with Constipation
8.5.2. Irritable Bowel Syndrome with Diarrhea
8.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
8.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
8.6.1. Hospital Pharmacies
8.6.2. Retail Pharmacies
8.6.3. Drug Stores
8.6.4. Online Pharmacies and Stores
8.6.5. Hypermarkets and Supermarkets
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Irritable Bowel Syndrome Treatment Market Outlook:
9.1. Key Highlights
9.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Product
9.2.3. By Indication
9.2.4. By Distribution Channel
9.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
9.4.1. Fiber Supplements
9.4.2. Anti-diarrheal
9.4.3. Anticholinergic and Antispasmodic
9.4.4. Antidepressant
9.4.5. Antibiotics
9.4.6. Alosetron
9.4.7. Lubiprostone
9.4.8. Linaclotide
9.4.9. NHE3
9.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
9.5.1. Irritable Bowel Syndrome with Constipation
9.5.2. Irritable Bowel Syndrome with Diarrhea
9.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
9.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
9.6.1. Hospital Pharmacies
9.6.2. Retail Pharmacies
9.6.3. Drug Stores
9.6.4. Online Pharmacies and Stores
9.6.5. Hypermarkets and Supermarkets
9.7. Market Attractiveness Analysis
10. Latin America Irritable Bowel Syndrome Treatment Market Outlook:
10.1. Key Highlights
10.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Product
10.2.3. By Indication
10.2.4. By Distribution Channel
10.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
10.4.1. Fiber Supplements
10.4.2. Anti-diarrheal
10.4.3. Anticholinergic and Antispasmodic
10.4.4. Antidepressant
10.4.5. Antibiotics
10.4.6. Alosetron
10.4.7. Lubiprostone
10.4.8. Linaclotide
10.4.9. NHE3
10.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
10.5.1. Irritable Bowel Syndrome with Constipation
10.5.2. Irritable Bowel Syndrome with Diarrhea
10.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
10.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
10.6.1. Hospital Pharmacies
10.6.2. Retail Pharmacies
10.6.3. Drug Stores
10.6.4. Online Pharmacies and Stores
10.6.5. Hypermarkets and Supermarkets
10.7. Market Attractiveness Analysis
11. Middle East & Africa Irritable Bowel Syndrome Treatment Market Outlook:
11.1. Key Highlights
11.2. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Product
11.2.3. By Indication
11.2.4. By Distribution Channel
11.3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Market Size (US$ Bn) Analysis and Forecast, By Product, 2025-2032
11.4.1. Fiber Supplements
11.4.2. Anti-diarrheal
11.4.3. Anticholinergic and Antispasmodic
11.4.4. Antidepressant
11.4.5. Antibiotics
11.4.6. Alosetron
11.4.7. Lubiprostone
11.4.8. Linaclotide
11.4.9. NHE3
11.5. Market Size (US$ Bn) Analysis and Forecast, By Indication, 2025-2032
11.5.1. Irritable Bowel Syndrome with Constipation
11.5.2. Irritable Bowel Syndrome with Diarrhea
11.5.3. Irritable Bowel Syndrome with alternating Constipation and Diarrhea
11.6. Market Size (US$ Bn) Analysis and Forecast, By Distribution Channel, 2025-2032
11.6.1. Hospital Pharmacies
11.6.2. Retail Pharmacies
11.6.3. Drug Stores
11.6.4. Online Pharmacies and Stores
11.6.5. Hypermarkets and Supermarkets
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Share Analysis, 2025
12.2. Market Structure
12.2.1. Competition Intensity Mapping By Market
12.2.2. Competition Dashboard
12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.3.1. Pfizer, Inc.
12.3.1.1. Overview
12.3.1.2. Segments and Product
12.3.1.3. Key Financials
12.3.1.4. Market Developments
12.3.1.5. Market Strategy
12.3.2. Takeda Pharmaceutical Company Limited
12.3.3. Pfizer, Inc.
12.3.4. Abbott Laboratories
12.3.5. Novartis AG
12.3.6. AstraZeneca PLC
12.3.7. Ironwood Pharmaceuticals Inc. and Allergan Plc
12.3.8. Bausch Health Companies Inc.
12.3.9. GlaxoSmithKline, Plc.
12.3.10. Lexicon Pharmaceuticals, Inc.
12.3.11. Sucampo Pharmaceuticals, Inc.
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á